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The precise measurement of epitope-specific cytotoxic T lymphocyte (CTL) responses in simian immunodeficiency virus
(SIV)- and simian–human immunodeficiency virus (SHIV)-infected or vaccinated rhesus monkeys has been important in the
evaluation of potential HIV vaccine strategies. This quantitation of CTL has been limited to date by the identification of only
one dominant SIV/SHIV epitope in these monkeys. We have recently defined a Nef CTL epitope p199RY (YTSGPGIRY) that
is recognized by CD8 T lymphocytes from all SIV/SHIV-infected Mamu-A*02 rhesus monkeys that have been evaluated.
We now measure the frequency of p199RY-specific CD8 T lymphocytes in the peripheral blood of these monkeys with
quantitative precision, using MHC class I/peptide tetramer staining and peptide-stimulated interferon- Elispot assays.
These epitope-specific CD8 T lymphocytes are present at a very high frequency and represent a significant proportion of
the entire SIV- or SHIV-specific CD8 T lymphocyte population in SIV/SHIV-infected Mamu-A*02 rhesus monkeys. Knowl-
edge of this dominant CTL epitope should prove valuable in the evaluation of HIV vaccine strategies using this animal model.inant;Nonhuman primate models are playing a vital role in
the development of HIV-1 vaccine strategies. Simian im-
munodeficiency virus (SIV)- and simian–human immuno-
deficiency virus (SHIV)-infected Indian-origin rhesus
monkeys are the most common of these models cur-
rently being employed (Amara et al., 2001; Barouch et al.,
2000b; Daniel et al., 1992; Hirsch et al., 1996; Rose et al.,
2001). With abundant evidence that virus-specific cyto-
toxic T lymphocyte (CTL) responses are critical for con-
trolling both HIV-1 and SIV/SHIV infections (Jin et al.,
1999; Koup et al., 1994; Kuroda et al., 1999; Schmitz et al.,
1999; Walker et al., 1986), it is important that SIV/SHIV-
specific CTL responses be measured in rhesus monkeys
in the course of evaluating these vaccine strategies
(Letvin, 1998).
The precise measurement of SIV/SHIV-specific CTL
responses in rhesus monkeys has been made possible
by our knowledge of predictable CTL epitopes in these
animals. In particular, the elucidation of a dominant SIV
Gag CTL epitope, the 9-amino-acid fragment p11C (CT-
PYDINQM) presented by the common Indian-origin rhe-
sus monkey MHC class I allele Mamu-A*01, has facili-
1 To whom correspondence and reprint requests should be ad-
dressed at the Division of Viral Pathogenesis, Department of Medicine,
Beth Israel Deaconess Medical Center, Harvard Medical School, Re-365tated the assessment of SIV/SHIV-specific CTL re-
sponses (Allen et al., 1998; Miller et al., 1991). SIV/SHIV-
infected or vaccinated Mamu-A*01 rhesus monkeys
predictably develop high-frequency CTL responses spe-
cific for this epitope (Egan et al., 2000; Seth et al., 1998;
Shen et al., 1991). A number of nondominant SHIV and
SIV epitopes that are presented to CD8 T lymphocytes
by Mamu-A*01 have also been defined (Allen et al.,
2000a; Egan et al., 1999; Furchner et al., 1999). Comple-
menting cytolytic assays with MHC class I/peptide tet-
ramer staining, enzyme-linked immunospot (Elispot) as-
says for interferon- production, and flow cytometry-
based assays for cytokine production has permitted the
measurement of CTL specific for these dominant and
subdominant viral epitopes with quantitative precision
(Allen et al., 2000b; Egan et al., 1999; Kuroda et al., 1998;
McKay et al., 2002).
The use of the rhesus monkey SIV and SHIV models
for evaluating CTL responses elicited by prototype HIV-1
vaccines has been limited to date by our knowledge of
only one dominant SIV/SHIV CTL epitope, the Mamu-
A*01-restricted p11C epitope. We have therefore sought
to characterize further dominant SIV/SHIV CTL epitopes
presented to CD8 T lymphocytes by other common
MHC class I alleles of rhesus monkeys. We recently
identified an SIV Nef CTL epitope, p199RY (YTSGPGIRY),© 2002 Elsevier Science (USA)
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that is presented by the common rhesus monkey MHC
class I molecule Mamu-A*02 (Robinson et al., 2001). In
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the present study, we have used tetramer staining and
Elispot interferon- production assays to determine the
relative dominance of this epitope-specific CTL re-
sponse.
RESULTS
Studies were initiated in SIV- and SHIV-infected
Mamu-A*02 Indian-origin rhesus monkeys to assess
the magnitude of CTL responses specific for the 9-amino-
acid Nef epitope p199RY. FourMamu-A*02Mamu-A*01
monkeys chronically infected with the nonpathogenic
virus SHIV-89.6 were initially selected for evaluation. As
expected from previous experience studying SHIV-89.6-
infected monkeys, these animals had normal peripheral
blood CD4 T lymphocyte counts and undetectable
plasma viral RNA as determined by bDNA assay (Table
1).
Peripheral blood from these monkeys was first evalu-
ated for the presence of Mamu-A*02/p199RY tetramer-
binding CD8 T lymphocytes. Gating on CD8CD3 lym-
phocytes, tetramer-binding cells were readily demon-
strated in the blood of all the SHIV-89.6-infected
monkeys. Moreover, the demonstration of this tetramer-
binding cell population was reproducible in repeated
evaluations of three to five blood samples from each of
these monkeys over a 2-month period of time. Tetramer-
binding cells constituted 0.04–0.93% of CD8CD3
cells, but 0.01% of CD8CD3 cells, CD8CD3
cells, CD8CD3 cells, or CD8CD3 cells (Fig. 1,
Table 2). There was some variation in the percentage of
tetramer-binding CD8 T lymphocytes in the evaluations
of repeated blood samples from the same monkey over
2 months (50% of the median), but the ranges for each
of these four monkeys did not overlap. There was thus a
clear hierarchy among the monkeys in the magnitude of
their CD8 T lymphocyte response to p199RY.
While these data clearly indicated that this Nef
epitope-specific CD8 T lymphocyte response was size-
able in the monkeys, they did not allow for an estimation
of the proportion of the monkeys’ total SIV/SHIV-specific
CD8 T lymphocyte population committed to this recog-
nition specificity. To evaluate this issue, peripheral blood
lymphocytes from the cohort of monkeys were assessed
in peptide/interferon- Elispot assays for the recognition
of all the structural and some of the regulatory viral gene
products of SIVmac239 or SHIV-89.6 (Fig. 2). The periph-
eral blood lymphocytes from one of these four monkeys
(18324) had a high background production of interferon-
in the absence of peptide exposure and therefore could
not be evaluated (data not shown). Lymphocytes from the
remaining three monkeys had high-frequency responses
to the pool of 125 overlapping 15-amino-acid peptides
TABLE 1
Clinical Status of Mamu-A*02 Rhesus Monkeys Used in This Study
Monkeys Mamu-A*01
Immunization
before infection Virus
CD4 T cells/l blood
(range during study)
Viral load
(RNA copies/ml plasma)
19242  None SHIV-89.6 1363–2055 500
18324  None SHIV-89.6 530–778 500
26795  None SHIV-89.6 940–1204 500
14282  None SHIV-89.6 744–1158 500
483  Yesa SHIV-89.6P 1056–2835 500
833  Yesa SHIV-89.6P 671–1683 500
19196  None SIVmac251 282–341 500
a Prior to infection, these monkeys were immunized with SIVmac239 Gag and HIV-1 Env 89.6P DNA vaccines and were also inoculated with a
plasmid encoding a fusion protein consisting of IL-2 and the Fc portion of IgG, as previously described (Barouch et al., 2000a,b).
FIG. 1. All SIV/SHIV-infected Mamu-A*02 rhesus monkeys have
Mamu-A*02/Nef p199RY tetramer-staining CD8 T lymphocytes in their
peripheral blood. Whole blood from monkeys 18324 (A), 26795 (B),
19242 (C), and 14282 (D) was stained with anti-CD3–APC, anti-CD8–
FITC, anti-CD8–ECD, and Mamu-A*02/Nef p199RY tetramer–PE and
analyzed by flow cytometry. Cells shown are gated on the lymphocyte
population that stained positively for CD3 and CD8.
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that spanned the SIV Gag protein. These lymphocyte
populations had a lower frequency response to the pool
of 62 overlapping 15-mers that spanned the SIV Nef
protein. Importantly, in lymphocyte populations from the
two animals (19242 and 26795) with high-frequency re-
sponses to the Nef peptide pool, most or all of that
response could be accounted for by the response to the
p199RY peptide alone. Moreover, the spot-forming cell
response to that Nef epitope peptide constituted a large
proportion of the entire virus-specific T cell response of
these monkeys. Lymphocytes from the third animal
(14282) had a low-frequency response to the Nef peptide
pool and a low-frequency response to the p199RY pep-
tide. This epitope-specific response also comprised a
small proportion of the monkey’s T lymphocyte response
to the Nef peptide pool. These tetramer and Elispot
studies indicate that the T cell immune response to the
p199RY Nef epitope can be a dominant one in Mamu-
A*02 rhesus monkeys.
It was then of interest to determine the dominance of
this Nef epitope-specific CTL response relative to other
SIV/SHIV epitope-specific CTL responses. We therefore
sought to evaluate the frequency of CTL specific for this
epitope in monkeys relative to the frequency of CTL
specific for the well-studied dominant Mamu-A*01-re-
stricted Gag p11C epitope. Three SIVmac- or SHIV-89.6P-
infected Mamu-A*01Mamu-A*02 monkeys were se-
lected for study. Peripheral blood was stained with the
Mamu-A*02/SIV Nef p199RY tetramer or with tetramers
containing Mamu-A*01 and one of the following epitope
peptides: the immunodominant SIV Gag p11C (CTPY-
DINQM) or the subdominant HIV Env p41A (YAPPITGQI),
SIV Env p15 (CAPPGYALL), SIV Env p54 (TVPWPNASL),
SIV Pol p68A (STPPLVRLV), or SIV Tat SL8 (TTPESANL).
In these three monkeys, Mamu-A*01/p11C tetramer-
binding cells constituted 1–9% of the circulating
CD8CD3 lymphocytes (Table 3). Lymphocyte popu-
lations from all three monkeys also had Mamu-A*02/
p199RY tetramer-binding CD8CD3 cells, but the
percentage varied greatly between animals. In the pe-
ripheral blood of monkey 483, there were consistently
more p199RY tetramer-binding CD8 T lymphocytes than
p11C tetramer-binding CD8 T lymphocytes, indicating
that a greater proportion of the circulating CD8 T lym-
phocytes in this monkey was specific for the p199RY
epitope than the p11C epitope. In monkey 833, however,
there were only approximately one-third as many
p199RY-specific CD8 T lymphocytes as p11C-specific
CD8 T lymphocytes. In monkey 19196, there were 15- to
30-fold fewer p199RY-specific CD8 T lymphocytes than
p11C-specific CD8 T lymphocytes.
Tetramer analyses of the peripheral blood of these
three monkeys were also carried out to quantitate CD8
T lymphocytes specific for Mamu-A*01-restricted sub-
dominant SIV/SHIV epitopes. No CD8 T lymphocytes
specific for Pol p68A, SIV Env p15, or SIV Env p54, and
FIG. 2. The immune response to p199RY by peripheral blood T
lymphocytes from Mamu-A*02 SHIV-infected rhesus monkeys consti-
tutes a significant portion of the T lymphocyte response to the entire
virus. PBL from the indicated monkeys were stimulated with peptides
or medium alone for 18 h. Peptides used were: p199RY at 1 g/ml; 2
pools containing a combined total of 85 overlapping 20-mers at 4 g/ml
each, representing the entire SHIV-89.6 Env protein; a pool of 125
overlapping 15-mers at 1 g/ml each, representing the entire SIV-
mac239 Gag protein; a pool of 62 overlapping 15-mers at 1 g/ml each,
representing the entire SIVmac239 Nef protein; and 2 pools containing
a combined total of 225 overlapping 15-mers at 1 g/ml each, repre-
senting the entire SIVmac239 Pol protein. Interferon--producing cells
were visualized by Elispot assay as described under Materials and
Methods. The number of spot-forming cells per 106 PBL is shown as the
mean  SD of triplicate wells.
TABLE 2
Mamu-A*02/Nef p199RY Tetramer Staining of Peripheral
Blood of Mamu-A*02Mamu-A*01 Rhesus Monkeys
Monkeys % tetramer staininga (median) Rangeb
19242 0.70 0.52–0.93
18324 0.28 0.28–0.38
26795 0.14 0.12–0.18
14282 0.08 0.04–0.11
a Percentage staining by tetrameric Mamu-A*02/Nef p199RY com-
plex on CD8 T lymphocytes, gating on CD8CD3 cells.
b of 3–5 peripheral blood samples per monkey, drawn at 2-week
intervals.
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very few CD8 T lymphocytes specific for SIV Tat SL8,
were demonstrable in the blood of the SIVmac-infected
Mamu-A*02Mamu-A*01 rhesus monkey 19196. The
peripheral blood of the SHIV-89.6P-infected monkeys 483
and 833 contained CD8 T lymphocytes specific for the
HIV Env p41A epitope. However, in the blood of monkey
483, Mamu-A*01/p41A tetramer-staining CD8 T lympho-
cytes were 10- to 20-fold less frequent than Mamu-A*02/
p199RY tetramer-staining CD8 T lymphocytes. In the
blood of monkey 833, Mamu-A*01/p41A tetramer-stain-
ing CD8 T lymphocytes were present at a frequency
that was greater than that of Mamu-A*02/p199RY tet-
ramer-staining CD8 T lymphocytes and less than that of
Mamu-A*01/p11C tetramer-staining CD8 T lympho-
cytes.
The relative frequencies of the SIV/SHIV epitope-spe-
cific T lymphocyte populations were then assessed in
the peripheral blood of these Mamu-A*02Mamu-A*01
rhesus monkeys using interferon- Elispot assays. Pe-
ripheral blood lymphocytes from all three monkeys had
very high frequency T lymphocyte responses to the pool
of peptides spanning the SIVmac Gag protein (Fig. 3).
This could be entirely accounted for by the responses to
the SIV Gag p11C peptide alone. Concordant with the
tetramer binding data, monkey 483 had a T lymphocyte
response to the Nef peptide pool that was as high in
frequency as that to the Gag peptide pool, and the
p199RY peptide-specific response was as high in fre-
quency as the monkey’s T lymphocyte response to the
entire pool of Nef peptides. The T lymphocytes of mon-
key 833 had a response to the Nef peptide pool that was
approximately half as large as their response to the Gag
peptide pool, and that response to Nef was also entirely
accounted for by the p199RY peptide-specific response.
The T lymphocytes of monkey 19196 had a much lower
frequency response to the Nef peptide pool, and only a
small proportion of that response was specific for
p199RY. The T lymphocytes of this monkey had a low-
frequency response to Tat SL8, but not to SIV Env p15,
SIV Env p54, or Pol p68A. Concordant with the tetramer-
binding data, the T lymphocytes of monkeys 483 and 833
demonstrated a low-frequency response to HIV Env
p41A, but not to Pol p68A. Thus, the Mamu-A*02-re-
stricted p199RY-specific T lymphocyte population can
make up a substantial proportion of the entire virus-
TABLE 3
Staining of Peripheral Blood of Mamu-A*02Mamu-A*01 Rhesus Monkeys by Mamu-A*02/Nef p199RY and Mamu-A*01/Epitope Peptide Tetramers
Median percentage tetramer staininga (range)b
Monkeys Nef p199RY Gag p11C Pol p68A HIV Env p41A Tat SL8 SIV Env p15 SIV Env p54
483 2.50 (1.80–3.18) 1.52 (1.37–1.63) 0.00 (0.00–0.01) 0.12 (0.08–0.16) — — —
833 0.54 (0.38–0.64) 2.01 (1.22–2.26) 0.01 (0.01–0.02) 1.36 (0.79–1.49) — — —
19196 0.18 (0.17–0.50) 5.24 (5.18–8.81) 0.01 (0.01–0.02) —c 0.07 (0.07–0.10) 0.01 (0.00–0.01) 0.03 (0.02–0.04)
a Percentage staining by tetramer complex on CD8 T lymphocytes, gating on CD8CD3 cells.
b Of 3–4 peripheral blood samples per monkey, drawn at 2-week intervals.
c Monkey was infected with a virus that did not express the epitope contained in the tetramer, and therefore PBL were not assessed for staining
with these particular tetramers.
FIG. 3. The immune response to p199RY by peripheral blood T
lymphocytes from Mamu-A*02Mamu-A*01 SHIV/SIV-infected rhesus
monkeys constitutes a significant portion of the T lymphocyte response
to the entire virus. The assay was performed as described in the legend
to Fig. 2, with the addition of wells containing the individual Mamu-
A*01-restricted epitope peptides p41A, p15, p54, p11C, p68A, and SL8,
each at a concentration of 1 g/ml. PBL from monkey 19196 were
stimulated with SIVmac239 Env peptide pools (two pools containing a
combined total of 220 overlapping 15-mers at 1 g/ml each, represent-
ing the entire SIVmac239 Env protein) rather than SHIV-89.6 Env pep-
tide pools. The number of spot-forming cells per 106 PBL is shown as
the mean  SD of triplicate wells.
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specific CD8 T lymphocyte population in SIV- and SHIV-
infected monkeys.
The frequency of Nef p199RY peptide-specific CD8 T
lymphocytes in the peripheral blood of most of these
SIV/SHIV-infected Mamu-A*02 rhesus monkeys was
high enough to account for the majority of the Nef-
specific CD8 T lymphocytes in those animals. To deter-
mine whether these p199RY-specific T lymphocytes ac-
tually constitute a majority of the Nef-specific T lympho-
cytes in these animals, a peptide pool was constructed
consisting of 15-amino-acid peptides overlapping by 11
amino acids and spanning the Nef protein minus the two
15-amino-acid peptides containing the p199RY peptide
sequence. This peptide pool was used in interferon-
Elispot assays to assess the frequency of interferon--
producing T lymphocytes that are specific for Nef
epitopes other than p199RY (Fig. 4). In three of the five
animals evaluated (483, 833, 19242), the p199RY-specific
T lymphocytes comprised almost the entire population
that recognized Nef. In the other two animals (26795,
19196), the p199RY-specific T lymphocytes comprised
one-third to one-half of the population that recognized
Nef.
DISCUSSION
The monkeys evaluated in the present study represent
an unusual population of infected animals in that they all
controlled their SIV/SHIV infections and maintained nor-
mal immune function. All of the monkeys had undetect-
able viral loads and normal peripheral blood CD4 T
lymphocyte counts (Table 1). The benign clinical course
in these monkeys can be explained by the fact that they
either were long-term survivors of SIVmac251 infections
or were infected with either the nonpathogenic SHIV-89.6
or the pathogenic SHIV-89.6P following immunization
with a gag-env DNA vaccine (Barouch et al., 2000b).
Nevertheless, while the CTL responses in these mon-
keys may have been more robust than might be expected
in animals infected with more highly pathogenic SIV or
SHIV isolates, the relative representation of CTL specific
for a variety of epitopes in a single animal likely reflected
what would be seen in an immunosuppressed, infected
animal.
A pooled peptide Elispot assay was used to evaluate
the relative dominance of the SIV Nef p199RY CTL
epitope among the other epitopes of the structural and
regulatory proteins of SIV. However, because of limita-
tions in reagent availability, the various peptide pools
employed in these studies differed in the length of their
constituent peptides. The peptides in the pools spanning
SIV Env, Gag, Nef, and Pol were all 15 amino acids in
length, the peptides in the pools spanning SHIV-89.6 Env
were 20 amino acids in length, and the individual epitope
peptides were 8 or 9 amino acids in length. It is possible
that the longer peptides might stimulate interferon- pro-
duction by T lymphocytes less efficiently than the shorter
peptides. Comparing the magnitude of T lymphocyte
responses to the various peptide pools could then be
misleading. However, when the two 15-amino-acid pep-
tides included in the Nef peptide pool that contained the
p199RY epitope were used individually in the assay, the
larger peptides stimulated numbers of T lymphocytes to
FIG. 4. The immune response to p199RY by peripheral blood T
lymphocytes from Mamu-A*02 SHIV/SIV-infected rhesus monkeys
constitutes a majority of the T lymphocyte response to the entire Nef
protein in most animals. The assay was performed as described in the
legends to Figs. 2 and 3, with the addition of wells containing the Nef
peptide pool without the two 15-amino-acid peptides that contain the
p199RY epitope sequence. The y axis scales are different for the
different animals. The number of spot-forming cells per 106 PBL is
shown as the mean  SD of triplicate wells.
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produce interferon- that were comparable to those
stimulated by the minimal epitope peptide (data not
shown). Furthermore, when a peptide pool spanning Nef,
but lacking the two 15-amino-acid peptides that contain
p199RY, was used to stimulate T lymphocytes, the num-
ber of interferon--producing cells was dramatically re-
duced in a majority of the monkeys. These findings
suggest that it should be valid to draw conclusions from
these pooled peptide Elispot studies.
An additional caveat that must be stated concerning
the Elispot studies is that both CD4 and CD8 T lym-
phocytes were present in the cell populations that were
evaluated. While both CD4 and CD8 T lymphocytes
would be stimulated by the pools of 15- or 20-amino-acid
peptides, only CD8 T lymphocytes would be stimulated
by the 9-amino-acid peptide epitope p199RY. Therefore,
the Elispot studies illustrate the proportion of the total T
lymphocyte population that is specific for the p199RY
epitope, which would have to be less than the proportion
of the CD8 T lymphocyte population alone that is spe-
cific for p199RY. The Elispot assays thus likely resulted in
an underestimate of the relative dominance of the
p199RY epitope for CD8 T lymphocytes.
The two quantitative assays used in these experi-
ments, tetramer staining and Elispot, yielded comparable
results. Among the different monkeys evaluated, those
whose peripheral blood lymphocytes (PBL) had a high
frequency of p199RY-specific T lymphocytes as deter-
mined by one assay also had a high frequency of these
cells as determined by the other assay. Moreover, the
relative frequency of T lymphocytes responding to
p199RY did not vary over months in an individual animal,
regardless of the assay used. Additionally, in each indi-
vidual Mamu-A*02MamuA*01 monkey, the relative fre-
quencies of peripheral T lymphocyte populations spe-
cific for p199RY, p11C, and other epitopes were constant
over time and did not vary with the assay used to eval-
uate them. This consistency validates the use of these
assays to measure the strength of epitope-specific T
lymphocyte responses with quantitative precision.
Dominance is a relative, rather than absolute, attribute
of CTL epitopes. In this study, we have demonstrated that
Nef p199RY is a relatively dominant epitope for CTL from
SIV/SHIV-infected Mamu-A*02 rhesus monkeys. The
PBL of all of the seven evaluated monkeys contained a
frequency of p199RY-specific T lymphocytes that was
high enough to be detected by both tetramer staining
and Elispot assay in freshly isolated blood cells. Among
these animals, the frequency of Mamu-A*02/p199RY-spe-
cific CTL in the peripheral blood varied. In one instance,
it was consistently higher than that of Mamu-A*01/p11C-
specific CTL; in another instance, it was more than 10-
fold lower. However, in PBL of all the evaluated monkeys,
the frequency of p199RY-specific CTL was higher than
that of CTL specific for any of the other epitopes evalu-
ated.
It has been suggested that a high-frequency epitope-
specific CTL response restricted by a given MHC class I
molecule can be inhibited at least partially in an individ-
ual by the generation of a dominant epitope-specific CTL
response restricted by a different MHC class I molecule
(Yewdell and Bennink, 1999). In fact, the frequency of
p199RY-specific T lymphocytes in PBL of the Mamu-
A*01Mamu-A*02 rhesus monkeys was comparable to
the frequency of these cells in PBL of the Mamu-
A*01Mamu-A*02 rhesus monkeys, despite the fact that
the Mamu-A*01Mamu-A*02 monkeys had a high-fre-
quency CTL response to the Gag p11C epitope. Notably,
monkey 483 had been immunized with SIVmac239 Gag
DNA and had developed Gag p11C-specific CTL prior to
infection with SHIV-89.6P. Nevertheless, following infec-
tion, the frequency of Nef p199RY-specific T lymphocytes
was actually higher than that of Gag p11C-specific T
lymphocytes in this monkey’s blood. Thus, no evidence
of competition between potential dominant epitopes was
observed in these monkeys.
Knowledge of a dominant SIV/SHIV CTL epitope and
the MHC class I molecule that presents that epitope
peptide to CD8 T lymphocytes allows one to monitor
AIDS vaccine trials in rhesus monkeys expressing that
MHC class I molecule with relative ease and extreme
quantitative precision. Evaluating the consequence of
infections in this subpopulation of monkeys also allows a
sophisticated analysis of viral escape from CTL recog-
nition. Since the Mamu-A*01-restricted SIV Gag p11C
epitope was the only dominant SIV/SHIV epitope previ-
ously defined in rhesus monkeys, highly quantitative
AIDS vaccine trials could only be performed in Mamu-
A*01 monkeys, animals that constitute approximately
20% of Indian-origin rhesus monkeys (Knapp et al., 1997).
With the definition of a second dominant SIV/SHIV
epitope presented to CD8 T lymphocytes by another
MHC class I allele, the number of rhesus monkeys that
can be used in these types of studies increases substan-
tially. Since Mamu-A*02 is expressed by approximately
20% of Indian-origin rhesus monkeys (unpublished ob-
servations), immunologically sophisticated AIDS vaccine
studies can now be carried out in 40% of all available
animals of this species. Moreover, observations made in
SIV/SHIV-infected Mamu-A*01 rhesus monkeys can
now be confirmed in rhesus monkeys using a different
MHC class I restriction element.
MATERIALS AND METHODS
Animals
All animals used in this study were Indian-origin rhe-
sus monkeys (Macaca mulatta). The monkeys had been
shown to express Mamu-A*02 by PCR typing (Robinson
et al., 2001). PCR typing documented that monkeys
19196, 483, and 833 also expressed Mamu-A*01 (Ba-
rouch et al., 2000a; and data not shown). Monkey 19196
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was chronically infected with SIVmac251. Monkeys
26795, 14282, 18324, 19242, 483, and 833 were chroni-
cally infected with SHIV-89.6 or SHIV-89.6P (Karlsson et
al., 1997; Reimann et al., 1996). The clinical status of the
monkeys during the course of the study is shown in
Table 1. Rhesus monkeys used in this study were main-
tained in accordance with the guidelines of the Institu-
tional Animal Care and Use Committee for Harvard Med-
ical School and the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal Re-
sources (U.S.) Committee on Care and Use of Laboratory
Animals, 1996).
CD4 counts and viral loads
Peripheral blood CD4 T lymphocyte counts were de-
termined by multiplying the total lymphocyte count (mea-
sured with a Coulter T-540, Beckman Coulter, Miami, FL)
by the percentage of CD3CD4 T lymphocytes as-
sessed by flow cytometry. Plasma viral RNA levels were
measured by SIV RNA 3.0 bDNA assay using a Quanti-
plex bDNA System 340, performed by Bayer Diagnostics
(Emeryville, CA), using probes which hybridize to the pol
gene of the viral RNA.
Peptides
Synthetic peptides were obtained from Quality Con-
trolled Biochemicals (Hopkinton, MA), a division of Bio-
source (Camarillo, CA). Peptides included SIVmac251
Nef p199RY (YTSGPGIRY), Gag p11C (CTPYDINQM), Pol
p68A (STPPLVRLV), Tat SL8 (TTPESANL), Env p15 (CAP-
PGYALL), Env p54 (TVPWPNASL), and HIV 89.6 Env p41A
(YAPPITGQI). Individual 15-amino-acid-length peptides,
overlapping by 11 amino acids and spanning the proteins
Env, Gag, Pol, and Nef from SIVmac239, as well as
individual 20-amino-acid-length peptides, overlapping by
10 amino acids, and spanning the Env protein from SHIV-
89.6, were obtained from the NIH AIDS Reagent Program
(McKesson BioServices Corp., Rockville, MD). They were
reconstituted in DMSO at 50 or 100 mg/ml and promptly
pooled to a concentration of 800 (SHIV-89.6 Env) or 400
g/ml (SIV pools). The Env and Pol peptides were so
numerous that two pools were required to span each
protein. Pools and individual peptides were stored at
80°C.
Construction of Mamu-A*02/p199RY tetrameric
complexes
DNA coding for the extracellular region of Mamu-A*02
was amplified by PCR with the 5 primer GTCACTGAATT-
CAGGAGGAATTTAAAATGGGCTCTCACTCCATGAGG and
the 3 primer GGACTGGGATCCCGGCTCCCATCTCAGG-
GTGAGGGG using a Mamu-A*02 plasmid provided by
Dr. David Watkins (University of Wisconsin) as the tem-
plate (Watanabe et al., 1994). The PCR product was
digested with EcoRI and BamHI and subcloned into the
expression plasmid Mamu-A*01/GlySer/BSP (BSP, BirA
substrate peptide) (Altman et al., 1996; Kuroda et al.,
1998), which contains the BSP at the 3 end. Subse-
quently, to increase the level of expression, the DNA
coding for the extracellular region of Mamu-A*02 was
reamplified from this plasmid by PCR with the 5 primer
GCACGCGCATATGGGTTCTCACTCTATGCGTTACTTCTA-
CACATCCGTG and the 3 primer GCCAAGCTTTTAACG-
ATGATTCC. The PCR product was ligated into the pCR-II
vector using the TA Cloning Kit (Invitrogen, Carlsbad,
CA), and digested with NdeI and SacI, and subcloned
into the expression plasmid PET23a/Mamu-A*01/BSP
(PET23a from Novagen, Madison, WI). This resulted in
an MHC fusion gene in which the sequence encoding
the first 230 amino acids—including the polymorphic
peptide-binding/epitope-determining 1 and 2 domains
and half of the conserved 2-microglobulin- and CD8-
binding 3 domain—was derived from Mamu-A*02; the
sequence encoding the last 46 amino acids—the other
half of the 3 domain—was from Mamu-A*01. In addi-
tion, use of a consensus primer resulted in a conserva-
tive substitution of valine for methionine at position 12.
The expressed protein was refolded in vitro with human
2-microglobulin (2m) in the presence of specific pep-
tide as described (Garboczi et al., 1992). The optimal
9-amino-acid peptide epitope of SIVmac251 Nef, p199RY
(YTSGPGIRY; Robinson et al., 2001), was used to induce
refolding of Mamu-A*02. The Mamu-A*02/p199RY/2m
monomers were purified by gel filtration on a Superdex
200 column (Pharmacia, Peapack, NJ) and biotinylated
enzymatically with BirA enzyme (Avidity, Denver, CO),
following the manufacturer’s instructions. The efficiency
of biotinylation was 80%. A Superdex 200 column was
used to remove free biotin from the monomers, and then
the biotinylated monomers were mixed with phyco-
erythrin (PE)-labeled streptavidin (Prozyme, San Leandro,
CA) at a molar ratio of 4:1 and titrated drop-wise to
maximize tetramer formation. The tetramer was stored at
a concentration of 25 g/ml in phosphate-buffered saline
(PBS) containing 0.3% bovine serum albumin, 0.1% so-
dium azide, and Protease Inhibitor Cocktail Set I (con-
taining AEBSF, aprotinin, E-64, EDTA, and leupeptin; Cal-
biochem, San Diego, CA) at 4°C. Mamu-A*02/p199RY
tetramer was used for staining at 125 ng per sample.
Tetramer staining of peptide-specific CD8 T
lymphocytes and flow cytometry
Soluble tetrameric complexes containing Mamu-A*01
and either p11C, p68A, p15, p54, p41A, or SL8 were
prepared as described elsewhere (Allen et al., 2000a;
Egan et al., 1999; Kuroda et al., 1998). PE-labeled
tetrameric complexes were used with fluorescein iso-
thiocyanate (FITC)-labeled anti-human CD8 (SK1;
BD Biosciences, San Diego, CA), energy-coupled dye
(ECD)-labeled anti-human CD8 (2ST8-5H7; Beckman
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Coulter), and allophycocyanin (APC)-labeled anti-rhesus
CD3 (FN18; custom conjugated by Beckman Coulter) to
stain epitope-specific CD8 T lymphocytes. One hundred
microliters of EDTA-preserved whole blood from rhesus
monkeys was incubated, first with PE-labeled tetramer
for 15 min at room temperature and then with anti-CD8–
FITC, anti-CD8–ECD and anti-CD3–APC for 15 min at
room temperature. The stained blood was then lysed on
an Immunoprep Reagent Q-Prep Workstation (Beckman
Coulter), washed with 4 ml of PBS, and fixed in 0.5 ml
PBS containing 1.5% paraformaldehyde. Samples were
analyzed by four-color flow cytometry on a Becton Dick-
enson FACSCalibur. To measure peripheral blood CD4
T lymphocyte counts, the percentage of CD3CD4 T
lymphocytes was assessed using PE-labeled anti-hu-
man CD4 (19Thy5D7; custom conjugated by Beckman
Coulter), anti-CD8–FITC, anti-CD8–ECD and anti-
CD3–APC as above.
Elispot analysis
EDTA-preserved whole blood from rhesus monkeys
was subjected to Ficoll–diatrizoate density-gradient cen-
trifugation to isolate leukocytes, and cells were then
seeded into 96-well plates (Millipore MultiScreen) that
had been coated overnight with anti-human interferon-
antibody (B27; PharMingen, San Diego, CA) at 10 g/ml
in Dulbecco’s phosphate-buffered saline (DPBS; GIBCO/
Invitrogen). Plates were then washed three times with
0.25% Tween 20 in DPBS (PBST). Plates were next
blocked for 2 hours at 37°C with 5% fetal calf serum
(FCS) in DPBS and then washed three times with PBST
and once with RPMI 1640 supplemented with 10% FCS.
Cells were seeded in RPMI with 10% FCS at a density of
2  105 cells per well in triplicate in the presence of
peptide (1 g/ml for 8- 15-amino-acid peptides; 4 g/ml
for 20-amino-acid peptides), phytohemagglutinin (PHAM)
(5 g/ml; Sigma Chemical Co., St. Louis, MO), or medium
alone. Plates were then incubated for 18 h at 37°C in a
5% CO2 atmosphere. Plates were washed nine times
with PBST and once with water and then incubated in the
presence of 2 g/ml biotinylated rabbit polyclonal anti-
human interferon- antiserum (Biosource) for 2 h at room
temperature. Plates were then washed again and incu-
bated with streptavidin–alkaline phosphatase (Southern
Biotechnology, Birmingham, AL) for 2 h at room temper-
ature. After a final rinse, a chromogenic substrate was
added (1-Step NBT/BCIP, Pierce, Rockford, IL). After
10–15 min, plates were washed thoroughly with water
and air dried. Spots were counted on an imaging system
(Hitech Instruments, Inc., a division of Olympus Scientific
Instruments, Edgemont, PA) using Image-Pro Plus im-
age-processing software.
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